Thought Leadership
We have vast experience supporting the P&MA launch strategy of high-profile brands and can help clients solve highly nuanced problems (i.e. HUB financial assistance program, HRU model.)
Showing 5 of 35 posts
September 1, 2021 | Blogs
Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape
CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.
August 2, 2021 | Blogs
CMS Hospital Pricing Transparency: One Price Fits All?
A CMS regulation from the Trump Administration requires hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021, with the rule still being widely ignored by hospitals.
July 20, 2021 | Podcasts
Trends and Dynamics of the Biosimilar Market across the EU, Latin America and Asia Pacific Regions
The biosimilar market is booming across the EU, Latin America and Asia Pacific regions. In this next episode of the multi-part biosimilar series, CBPartners’ regional Centers of Excellence teams provide expert insights into the trends and dynamics of the biosimilar market, with a particular focus on these regions.
March 8, 2021 | Podcasts
USA Policy Expectations for a New Administration
This episode, which kicks off season two of CBPartners’ Pharma Take-away, discusses the possible evolution of healthcare and healthcare policy in the United States, and explores the changes we may expect over the next few years as a result of the presidential election party transition.
February 19, 2021 | Infographics
KAISER Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral
KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health concerns is a step towards modernizing healthcare and represents a very structured approach to real-world data generation.